CIPLA Inorganic augmentation to US business
|
|
- Cecil Rich
- 6 years ago
- Views:
Transcription
1 EVENT UPDATE CIPLA Inorganic augmentation to US business India Equity Research Pharmaceuticals Cipla (CIPL) has announced an agreement to acquire 2 US generic companies Invagen and Exelan subsidiaries of Hetero Pharma. The combined cash consideration is USD550mn, representing ~2 EV/ Sales at MAT June 2015 revenue run rate. While margins of the acquired business have not been disclosed, CIPL stated that the deal will be EPS accretive. Though the deal brings a reasonable amount of US-based manufacturing, critical mass and access, it does not add new product development platforms. While the pipeline of acquired companies (30 ANDAs, of which 5 are FTFs) indicates steady portfolio growth, maintaining manufacturing compliance (form 483 observations from inspections during March 2015 and May 2015) will be critical for an attractive payback. Maintain BUY. Deal outline indicates fair price paid for essential critical mass The CIPL deal indicates that generic players are chasing assets comprising: (i) US-based manufacturing; and (ii) access to US government/ institutional business, along with a near-term pipeline to augment near-term growth. While Invagen brings US-based manufacturing and near-term revenue (40 approved/ 30 pipeline ANDAs, with 5 FTFs), Exelan gives access to incremental business channels... but brings associated risks We believe, if not already resolved, closure of March 2015 and May 2015 form 483s is critical so that the critical near-term opportunities (Nexium, Renagel, Renvela, etc.) can be monetised and payback to the deal will be more attractive. Outlook and valuations: Operating leverage story; maintain BUY Immediate critical mass was essential for CIPL s profitability post: (i) investing in US front end; and (ii) customer consolidation in US, as significant contribution from its organic pipeline in some time away. In our view, while the deal represents an essential accretion, it will limit CIPL s agility to invest in additional development platforms. We maintain BUY/SO. EDELWEISS 4D RATINGS Absolute Rating Rating Relative to Sector Risk Rating Relative to Sector Sector Relative to Market BUY Outperformer Low Equalweight MARKET DATA (R: CIPL.BO, B: CIPLA IN) CMP : INR 656 Target Price : INR week range (INR) : 753 / 546 Share in issue (mn) : M cap (INR bn/usd mn) : 527 / 8,363 Avg. Daily Vol.BSE/NSE( 000) : 2,045.3 SHARE HOLDING PATTERN (%) Current Q4FY15 Q3FY15 Promoters * MF's, FI's & BK s FII's Others * Promoters pledged shares (% of share in issue) : NIL PRICE PERFORMANCE (%) Stock Nifty EW Pharma Index 1 month (8.0) (8.4) months 3.2 (3.8) months 18.5 (3.6) 29.0 Financials (INR mn) Year to March FY14 FY15E FY16E FY17E Revenues 101, , , ,038 Rev. growth (%) EBITDA 20,956 21,617 32,885 39,917 Adjusted Profit 12,711 11,807 19,044 23,845 Adjusted diluted EPS (INR) EPS Growth (%) (5.5) (7.1) Diluted P/E (x) EV/EBITDA (x) ROAE (%) Edelweiss Research is also available on Bloomberg EDEL <GO>, Thomson First Call, Reuters and Factset. Rahul Solanki rahul.solanki@edelweissfin.com September 4, 2015 Edelweiss Securities Limited
2 Pharmaceuticals Details of acquired businesses Invagen Incorporated in Deal consideration: USD500mn. Turnover: USD130mn/135mn/190mn in CY12/13/14. Large capacity manufacturing base in Hauppauge, New York, and a skilled US-based R&D organisation. 40 approved ANDAs, of which 32 have been launched. With a manufacturing footprint of ~350,000 sq ft of GMP area, Invagen has 3 units located in Long Island, NY, with a total production capacity of 12bn tablets and capsules per annum and about 500 employees. US front-end access to wholesalers/ retailers. Form 483s issued in March 2015 and May Table 1: Invagen s approved ANDAs Alfuzosin ER tablet Amlodipine Besylate tablet Benztropine Mesylate tablet Calcium Acetate capsule Calcium Acetate tablet Carbinoxamine Maleate tablet Citalopram Hydrobromide tablet Cyclobenzaprine Hydrochloride tablet Escitalopram Oxalate tablet Folic acid tablet Fosinopril Sodium tablet Fosinopril Sodium/ HCTZ tablet Gabapentin capsule Gabapentin tablet Gemfibrozil tablet Glimepiride tablet Hydralazine Hydrochloride tablet Quinapril Hydrochloride/ HCTZ tablet Hydroxyzine Hydrochloride tablet Levetiracetam tablet Lisinopril tablet Meprobamate tablet Nabumetone tablet Naproxen DR tablet Orphenadrine Citrate ER tablet Phentermine Hydrochloride capsule Phentermine Hydrochloride tablet Quinapril Hydrochloride tablet Raloxifene Hydrochloride tablet Ramipril capsule Rizatriptan Benzoate tablet Setraline Hydrochloride tablet Terbinafine Hydrochloride tablet Topiramate tablet Trandolapril tablet Warfarin Sodium tablet Zolmitriptan tablet Zolpidem Tartarate tablet Zonisamide capsule Source: FDA 2 Edelweiss Securities Limited
3 Cipla Table 2: Invagen s Para-IV filings Brand Market Size (USD mn) Viibryd 160 Fosrenol 115 Latuda 500 Renagel Renvela 600 PhosLo Gelcaps 50 Evista 850 Zoloft 450 Viagra 1150 Propecia 100 Prezista 1200 Actos 200 Source: Bloomberg Exelan Incorporated in Deal consideration: USD50mn. Turnover: USD2mn/14mn/28mn in CY12/13/14. Access to government and institutional market in the US. Manufacture and distribution services are provided by affiliate partners. Table 3: Marketed products Alfuzosin Hydrochloride Amlodipine Citalopram Hydrobromide Escitalopram Folic acid Fosinopril Finasteride Gabapentin Gemfibrozil Levetiracetam Lisinopril Nabumetone Ramipril Setraline Hydrochloride Terbinafine Hydrochloride Topiramate Zonisamide Source: Company website 3 Edelweiss Securities Limited
4 Pharmaceuticals Company Description Cipla is a global Pharma company with a geographically diversified presence and products registered in more than 170 countries. The India branded formulations accounts for more than 40% of its business and Cipla is among the top three players in the market. In the past, Cipla believed in the partnership model for international markets but over the last three years the company is undergoing a strategic shift and has started setting up its own front end. Cipla is also a well-known global player in the inhalers and antiretrovirals space. Going forward the company expects launch of combination inhalers in the larger markets of US and EU and setting up of own front ends to drive growth. Investment Theme We believe Cipla is headed in the right direction as investments in pipeline/front end begin to deliver. We expect steady growth and margin recovery going forward as acquired businesses and own sales in US/EU start ramping up. Earnings to be driven by operating leverage benefits on initiation of sales from US and EU through own front end, ramp up in Dymista (nasal spray with partner Meda) and cost synergies in South Africa (recently acquired). The launch of combination inhalers in EU validates its capabilities in the space and expect this business to be a long term driver. Key Risks Delay in approvals in US and EU / slower than expected ramp up in the combination inhalers segment Currency appreciation: more than 60% of the business is international and any substantial movement of the currency could hurt. 4 Edelweiss Securities Limited
5 Cipla Financial Statements Key Assumptions Macro GDP(Y-o-Y %) Inflation (Avg) Repo rate (exit rate) USD/INR (Avg) Sector India pharma market growth (Y-o-Y) % Company India sales (INR mn) 40,907 48,222 54,973 62,669 % change Export formulations (USD mn) 815 1,007 1,306 1,763 % change API (USD mn) % change Tech Income (USD mn) % of Other operating income EBITDA margins (%) R&D (% of sales) USD/INR (Avg) Capex (USD mn) Net debt to equity ratio(x) Income statement (INR mn) Gross revenues 98, , , ,375 Net revenue 97, , , ,415 Other Operating Income 3,476 4,630 5,225 5,624 Income from operations 101, , , ,038 Materials costs 38,748 41,924 49,007 57,628 Employee costs 13,940 19,737 24,079 26,246 R&D Cost 5,119 6,747 11,531 12,528 Total SG&A expenses 22,241 23,430 26,636 30,719 EBITDA 20,956 21,617 32,885 39,917 Operating profit 20,956 21,617 32,885 39,917 EBIT 17,622 16,570 26,963 33,355 Add: Other income 1,889 1,656 1,821 2,003 Less: Interest Expense 711 1,683 1,922 1,802 Profit Before Tax 18,800 16,542 26,862 33,556 Less: Provision for Tax 4,634 4,000 6,715 8,389 Less: Minority Interest ,102 1,322 Reported Profit 14,167 11,807 19,044 23,845 Less: Exceptional Items (Net of 1, Adjusted Profit 12,711 11,807 19,044 23,845 No. of Shares outstanding (mn) Adjusted Basic EPS No. of Diluted shares outstanding Adjusted Diluted EPS Adjusted Cash EPS Dividend per share (DPS) Dividend Payout Ratio (%) Common size metrics Operating expenses Materials costs Staff costs S G & A expenses R & D cost Depreciation Interest Expense EBITDA margins Net Profit margins Growth ratios (%) Revenues EBITDA PBT 9.1 (12.0) Adjusted Profit (5.5) (7.1) EPS (5.5) (7.1) Edelweiss Securities Limited
6 Pharmaceuticals Balance sheet (INR mn) As on 31st March FY14 FY15 FY16E FY17E Share capital 1,606 1,606 1,606 1,606 Reserves & Surplus 98, , , ,812 Shareholders' funds 100, , , ,418 Minority Interest 496 1,805 1,805 1,805 Short term borrowings 9,105 13,925 11,925 11,925 Long term borrowings 3,179 3,093 3,093 3,093 Total Borrowings 12,283 17,018 15,018 15,018 Long Term Liabilities & Provisions 1,100 2,009 2,009 2,009 Deferred Tax Liability (net) 3,090 2,846 2,846 2,846 Sources of funds 117, , , ,096 Gross Block 60,443 70,031 78,031 86,031 Depreciation 3,334 5,047 5,922 6,562 Net Block 40,034 42,712 44,789 46,227 Capital work in progress 4,418 5,809 5,809 5,809 Intangible Assets 24,931 25,585 25,585 25,585 Total Fixed Assets 69,383 74,106 76,183 77,621 Non current investments 3,971 2,498 2,498 2,498 Cash and cash equivalents 4,866 9,543 11,514 19,644 Inventories 28,953 37,806 45,367 54,441 Sundry Debtors 16,389 20,043 24,051 28,861 Loans & Advances 8,970 10,043 11,458 13,156 Other Current Assets 1,472 2,666 2,956 3,304 Total Current Assets (ex cash) 55,783 70,558 83,833 99,762 Trade payable 9,795 15,772 18,927 22,712 Other Current Liabilities & Short 6,736 9,239 9,828 12,716 Total Current Liabilities & 16,531 25,011 28,755 35,428 Net Current Assets (ex cash) 39,252 45,547 55,078 64,334 Uses of funds 117, , , ,096 Book Value per share (INR) Free cash flow (INR mn) Reported Profit 14,167 11,807 19,044 23,845 Add: Depreciation 3,334 5,047 5,922 6,562 Interest (Net of Tax) 536 1,276 1,442 1,352 Others (271) (579) (340) (29) Less: Changes in WC (40,226) 24,906 10,755 10,578 Operating cash flow 57,990 (7,354) 15,313 21,152 Less: Capex 7,908 9,116 8,000 8,000 Free Cash Flow 50,082 (16,470) 7,313 13,152 Cash flow metrics Operating cash flow 57,990 (7,354) 15,313 21,152 Investing cash flow (58,654) (9,046) (8,000) (8,000) Financing cash flow ,291 (5,342) (5,022) Net cash Flow 322 3,891 1,971 8,130 Capex (7,908) (9,116) (8,000) (8,000) Dividend paid (1,879) (1,658) (3,342) (5,022) Profitability and efficiency ratios Return on Average Equity (ROAE) Pre-tax Return on Capital Inventory Days Debtors Days Payable Days Cash Conversion Cycle Current Ratio Gross Debt/EBITDA Gross Debt/Equity Adjusted Debt/Equity Net Debt/Equity Interest Coverage Ratio Operating ratios Total Asset Turnover Fixed Asset Turnover Equity Turnover Valuation parameters Adjusted Diluted EPS (INR) Y-o-Y growth (%) (5.5) (7.1) Adjusted Cash EPS (INR) Diluted Price to Earnings Ratio Price to Book Ratio (P/B) (x) Enterprise Value / Sales (x) , Enterprise Value / EBITDA (x) Dividend Yield (%) Peer comparison valuation Market cap Core EV/EBITDA (X) PE based on core EPS Return on Average Equity Name (USD mn) FY16E FY17E FY16E FY17E FY16E FY17E Cipla 8, Dr.Reddys Laboratories 10, Lupin 13, Sun Pharmaceuticals Industries 34, AVERAGE Source: Edelweiss research 6 Edelweiss Securities Limited
7 Cipla Additional Data Directors Data Dr. Y.K. Hamied Chairman M.K. Hamied Non-Executive Vice-Chairman Subhanu Saxena Managing Director & Global CEO S. Radhakrishnan Whole-time Director Rajesh Garg Executive Director & CFO Dr. H.R. Manchanda Non-Executive Director Ashok Sinha Non-Executive Director V.C. Kotwal Non-Executive Director Dr. Peter Mugyenyi Non-Executive Director Adil Zainulbhai Non-Executive Director Auditors - V. Sankar Aiyar & Co.,R.G.N. Price & Co. *as per last annual report Holding Top10 Perc. Holding Perc. Holding Hamied yusuf k Life insurance corp 5.51 Hamied farida 5.22 Hamied mustafa kamil 4.94 Oppenheimer funds in 2.33 Ahmed sophie 1.93 Virtus investment ad 1.64 Blackrock 1.43 Hamied kamil mustafa 1.36 Vontobel india fund 1.33 *in last one year Bulk Deals Data Acquired / Seller B/S Qty Traded Price No Data Available *in last one year Insider Trades Reporting Data Acquired / Seller B/S Qty Traded No Data Available *in last one year 7 Edelweiss Securities Limited
8 RATING & INTERPRETATION Company Absolute reco Relative reco Relative risk Company Absolute reco Relative reco Relative Risk Apollo Hospitals Enterprise BUY None None Aurobindo Pharma HOLD SP H Cadila Healthcare BUY SP L Cipla BUY SO L Divi's Laboratories REDUCE SU M Dr.Reddys Laboratories BUY SO M Glenmark Pharmaceuticals HOLD SP H Ipca Laboratories REDUCE SU H Lupin HOLD SO M Sun Pharmaceuticals Industries BUY SO M Torrent Pharmaceuticals HOLD SP H ABSOLUTE RATING Ratings Expected absolute returns over 12 months Buy More than 15% Hold Between 15% and - 5% Reduce Less than -5% RELATIVE RETURNS RATING Ratings Sector Outperformer (SO) Sector Performer (SP) Criteria Stock return > 1.25 x Sector return Stock return > 0.75 x Sector return Stock return < 1.25 x Sector return Sector Underperformer (SU) Stock return < 0.75 x Sector return Sector return is market cap weighted average return for the coverage universe within the sector RELATIVE RISK RATING Ratings Low (L) Medium (M) High (H) Criteria Bottom 1/3rd percentile in the sector Middle 1/3rd percentile in the sector Top 1/3rd percentile in the sector Risk ratings are based on Edelweiss risk model SECTOR RATING Ratings Overweight (OW) Equalweight (EW) Criteria Sector return > 1.25 x Nifty return Sector return > 0.75 x Nifty return Sector return < 1.25 x Nifty return Underweight (UW) Sector return < 0.75 x Nifty return 8 Edelweiss Securities Limited
9 Cipla Edelweiss Securities Limited, Edelweiss House, off C.S.T. Road, Kalina, Mumbai Board: (91-22) , Nirav Sheth Head Research Coverage group(s) of stocks by primary analyst(s): Pharmaceuticals Apollo Hospitals Enterprise, Aurobindo Pharma, Cadila Healthcare, Cipla, Divi's Laboratories, Dr.Reddys Laboratories, Glenmark Pharmaceuticals, Ipca Laboratories, Lupin, Sun Pharmaceuticals Industries, Torrent Pharmaceuticals Recent Research Date Company Title Price (INR) Recos 14-Aug-15 Cadila Healthcare Moraiya risks lurk; Result Update 14-Aug-15 Cipla Blowout quarter; pre-poned investments may curb margin; Result Update 14-Aug-15 Aurobindo Pharma US growth visibility improves; Result Update 1,984 Buy 740 Buy 762 Hold Distribution of Ratings / Market Cap Edelweiss Research Coverage Universe Buy Hold Reduce Total Rating Interpretation Rating Expected to Rating Distribution* * stocks under review > 50bn Between 10bn and 50 bn < 10bn Market Cap (INR) Buy Hold Reduce appreciate more than 15% over a 12-month period appreciate up to 15% over a 12-month period depreciate more than 5% over a 12-month period One year price chart Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 (INR) Cipla 9 Edelweiss Securities Limited
10 Pharmaceuticals DISCLAIMER Edelweiss Securities Limited ( ESL or Research Entity ) is regulated by the Securities and Exchange Board of India ( SEBI ) and is licensed to carry on the business of broking, depository services and related activities. The business of ESL and its Associates (list available on are organized around five broad business groups Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. This Report has been prepared by Edelweiss Securities Limited in the capacity of a Research Analyst having SEBI Registration No.INH and distributed as per SEBI (Research Analysts) Regulations This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors. This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ESL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. ESL reserves the right to make modifications and alterations to this statement as may be required from time to time. ESL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. ESL is committed to providing independent and transparent recommendation to its clients. Neither ESL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance.the disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of ESL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of ESL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders. ESL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the ESL to present the data. In no event shall ESL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the ESL through this report. We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report. ESL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. ESL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with ESL. 10 Edelweiss Securities Limited
11 Cipla ESL or its associates may have received compensation from the subject company in the past 12 months. ESL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. ESL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or ESL s associates may have financial interest in the subject company. ESL and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. ESL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Participants in foreign exchange transactions may incur risks arising from several factors, including the following: ( i) exchange rates can be volatile and are subject to large fluctuations; ( ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk. Research analyst has served as an officer, director or employee of subject Company: No ESL has financial interest in the subject companies: No ESL s Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report. Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No ESL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No Subject company may have been client during twelve months preceding the date of distribution of the research report. There were no instances of non-compliance by ESL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years except that ESL had submitted an offer of settlement with Securities and Exchange commission, USA (SEC) and the same has been accepted by SEC without admitting or denying the findings in relation to their charges of non registration as a broker dealer. A graph of daily closing prices of the securities is also available at Analyst Certification: The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Additional Disclaimers Disclaimer for U.S. Persons This research report is a product of Edelweiss Securities Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution by Edelweiss Securities Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. 11 Edelweiss Securities Limited
12 Pharmaceuticals In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Edelweiss Securities Limited has entered into an agreement with a U.S. registered broker-dealer, Edelweiss Financial Services Inc. ("EFSI"). Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc. Disclaimer for U.K. Persons The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the Order ); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as relevant persons ). This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. Disclaimer for Canadian Persons This research report is a product of Edelweiss Securities Limited ("ESL"), which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst. This report is intended for distribution by ESL only to "Permitted Clients" (as defined in National Instrument ("NI ")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person. ESL is relying on an exemption from the adviser and/or dealer registration requirements under NI available to certain international advisers and/or dealers. Please be advised that (i) ESL is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) ESL's head office or principal place of business is located in India; (iii) all or substantially all of ESL's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against ESL because of the above; and (v) the name and address of the ESL's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario M5J 2T3 Canada. Disclaimer for Singapore Persons In Singapore, this report is being distributed by Edelweiss Investment Advisors Private Limited ("EIAPL") (Co. Reg. No H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to EIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact EIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors. Copyright 2009 Edelweiss Research (Edelweiss Securities Ltd). All rights reserved Access the entire repository of Edelweiss Research on 12 Edelweiss Securities Limited
RELIANCE INDUSTRIES LIMITED
RELIANCE INDUSTRIES LIMITED EDELSTAR FUNDAMENTAL RESEARCH Business Overview RIL is the largest private player in the refining, petrochemical and E&P sectors in India. While RIL s refining complex in Jamnagar
More informationPHARMACEUTICALS Drug pricing probe: Storm in a teacup?
SECTOR UPDATE PHARMACEUTICALS Drug pricing probe: Storm in a teacup? India Equity Research Pharmaceuticals The US presidential election has fueled much populist debate on drug pricing, beating down pharma
More informationHINDUSTAN UNILEVER Indulekha allure for the tresses
FLASH NOTE FLASH HINDUSTAN UNILEVER Indulekha allure for the tresses India Equity Research Consumer Goods Hindustan Unilever (HUL) has acquired premium ayurvedic hair oil brands Indulekha and Vayodha for
More informationJSW Steel EDELSTAR FUNDAMENTAL RESEARCH
JSW Steel EDELSTAR FUNDAMENTAL RESEARCH Business Overview JSW, part of the USD8bn O.P. Jindal Group, was incorporated as Jindal Vijaynagar Steel JVSL). It began operations in 1999 with the commissioning
More informationUjjivan Financial Services Ltd.: Q3FY18 Result Update
Edelweiss Investment Research Ujjivan Financial Services Ltd.: Q3FY18 Result Update Good show; Robust outlook Ujjivan Financial Services Ltd. (UFS) reported a mixed set of numbers in its Q3FY18 financial
More informationJindal Stainless Hisar Ltd.: Q3FY18 Result Update
Edelweiss Investment Research Jindal Stainless Hisar Ltd.: Q3FY18 Result Update Stronger volumes & profitability improvement continues Jindal stainless (Hisar)(JSHL) reported healthy growth of 35.2% in
More informationEconomic Spotlight. Current Account Deficit Narrows. Edelweiss Investment Research
Economic Spotlight Edelweiss Investment Research Current Account Deficit Narrows India s current account deficit (CAD) at $ 7.2 billion (1.2 per cent of GDP) in Q2 of 2017-18 narrowed sharply from $ 15.0
More informationTrident Ltd.: Q1FY18 Result Update
Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Edelweiss Investment Research Trident Ltd.: Q1FY18 Result Update
More informationPNC Infratech Ltd.: Q3FY18 Result Update
Edelweiss Investment Research PNC Infratech Ltd.: Q3FY18 Result Update Execution pickup to drive growth PNC Infratech (PNC), one of the largest EPC road constructors in India with more than INR 10,000
More informationEconomic Spotlight. Revised Govt. Borrowing Means More Fiscal Room. Edelweiss Investment Research
Edelweiss Investment Research Economic Spotlight Revised Govt. Borrowing Means More Fiscal Room Extra Government Borrowing in line with our expectations Government borrowing is a source of financing of
More informationTrident Ltd: Q2FY18 Result Update
Edelweiss Investment Research Trident Ltd: Q2FY18 Result Update Weak results; Strong Outlook CMP INR 92 Target INR 118 Rating: BUY Upside: 30% Date: 06 th November 2017 After delivering a strong ~25% topline
More informationDilip Buildcon Ltd.: Q3FY18 Result Update
Edelweiss Investment Research Dilip Buildcon Ltd.: Q3FY18 Result Update From Sub-contractor to Marquee EPC Play CMP INR: 981 Rating: BUY Target Price INR: 1,204 Upside: 22% Dilip Buildcon (DBL), the largest
More informationCIPLA Another quarter misses the mark
RESULT UPDATE CIPLA Another quarter misses the mark India Equity Research Pharmaceuticals Cipla s Q4FY17 revenue grew mere 7% YoY due to dip in India and emerging markets. US business was flat through
More informationEmami Ltd. EDELSTAR FUNDAMENTAL RESEARCH
Emami Ltd. EDELSTAR FUNDAMENTAL RESEARCH Business Overview Emami is a leading FMCG player in India, operating in certain attractive segments such as skin care and hair oil. The company is promoted by Kolkata
More informationTATA CONSULTANCY SERVICES BFSI, retail turnaround awaited
VISIT NOTE TATA CONSULTANCY SERVICES BFSI, retail turnaround awaited India Equity Research IT Key highlights of our recent interaction with TCS top management are: 1) softness in BFSI & retail verticals
More informationTransformer and Rectifier (India) Ltd: Q4FY17 Result Update
Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 Edelweiss Investment Research Transformer and Rectifier (India) Ltd: Q4FY17 Result Update
More informationPerformance Tracker Equity
Performance Tracker Equity For queries/feedback please contact: Phone: 022-4079 5108 Email:edelinvest.technical@edelcap.com Snapshot for the month of September 2017 PERFORMANCE HIGHLIGHT FOR SEPTEMBER
More informationZee Learn Ltd.: Q2FY18 Result Update
Edelweiss Investment Research Zee Learn Ltd.: Q2FY18 Result Update Margin improved with healthy growth CMP INR 47 Target INR 80 Rating: BUY Upside: 71% Date: 17 th October 2017 Zee Learn Ltd. (ZLL) reported
More informationRatnamani Metals & Tubes Ltd.: Q1FY18 Results Update
Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Edelweiss Investment Research Ratnamani Metals & Tubes Ltd.: Q1FY18
More informationBRIGADE ENTERPRISES Mixed quarter; scale up ahead
RESULT UPDATE BRIGADE ENTERPRISES Mixed quarter; scale up ahead India Equity Research Real Estate Brigade Enterprises (BEL) Q1FY18 net profit missed our estimate; new sales were slow due to RERA and GST
More informationAPOLLO HOSPITALS On track
RESULT UPDATE APOLLO HOSPITALS On track India Equity Research Pharmaceuticals Apollo Hospitals (APHS) Q1FY14 standalone results were in line with revenue growth of 15% YoY, led by 11% growth in hospitals
More informationCRISIL Slowdown in research and rating
India Midcaps RESULT UPDATE CRISIL Slowdown in research and rating India Equity Research Credit Rating CRISIL s Q1CY18 numbers came in line with estimates with revenue growing 4.6% YoY and EBITDA jumping
More informationOBEROI REALTY Value accretive Thane land buy; scope for further NAV growth
COMPANY UPDATE OBEROI REALTY Value accretive Thane land buy; scope for further NAV growth India Equity Research Real Estate Oberoi Realty has won the bid to acquire GSK Pharma s 60acre land parcel in Thane
More informationOIL AND GAS Expert speak: BP s World Energy Outlook Oversupplied!
SECTOR UPDATE OIL AND GAS Expert speak: BP s World Energy Outlook Oversupplied! India Equity Research Oil, Gas and Services We had the privilege of hosting Dr. Kaushik Deb, Global Head of Gas analysis
More informationFirst Flash: Butterfly Gandhimathi Appliances Ltd
Edel Invest Research First Flash: Butterfly Gandhimathi Appliances Ltd Brand play; intensified focus; available at cheap valuation Company structure Butterfly Gandhimathi Appliances (BGAL) is a leading
More informationCADILA HEALTHCARE. Waiting for Moraiya clearance with bated breath. Earnings beat estimate. Strong acceleration ahead
RESULT UPDATE CADILA HEALTHCARE Waiting for Moraiya clearance with bated breath India Equity Research Pharmaceuticals Cadila Healthcare s (CDH) Q4FY17 earnings surpassed expectations driven by EBITDA beat.
More informationORIENT REFRACTORIES. Exports strong; domestic revives. Robust export growth sustains; domestic demand driven by bricks. Key growth drivers
RESULT UPDATE ORIENT REFRACTORIES Exports strong; domestic revives India Equity Research Miscellaneous Orient Refractories (ORL) Q4FY18 revenue soared ~41% YoY (20% above estimate) led by jump in both
More informationAPOLLO HOSPITALS. Navi Mumbai facility ramping up well. State-of-the-art facility on ramp up mode. Navi Mumbai investment rationale appears compelling
VISIT NOTE APOLLO HOSPITALS Navi Mumbai facility ramping up well India Equity Research Pharmaceuticals Apollo Hospitals (APHS) past 5 years declining margin trajectory is set for an inflection point in
More informationKey estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,
: price: EPS: How does our one year outlook change? We maintain rating on Aurobindo post the company s 3QFY16 results. Revenue growth for the quarter was 10% yoy: US sales of $238mn (vs. estimate of $251mn
More informationTATA POWER CO Tripped by one off
RESULT UPDATE TATA POWER CO Tripped by one off India Equity Research Power Tata Power (TPWR) reported a loss of INR2.6bn in Q4FY17 as it had to write off advances extended to Tata Sons as its share of
More informationJAYPEE INFRATECH Cost overrun erodes valuation
RESULT UPDATE JAYPEE INFRATECH Cost overrun erodes valuation India Equity Research Real Estate Jaypee Infratech s (JPIN) Q2FY12 profit of INR3.1bn was higher than estimates due to higher revenue bookings
More informationDr Reddy s Laboratories
: price: EPS: How does our one year outlook change? We maintain rating on DRRD post the company s 3QFY16 results Revenue growth for the quarter was muted (3% yoy) due to disappointing performances in Russia
More informationULTRATECH CEMENT Improved demand outlook
RESULT UPDATE ULTRATECH CEMENT Improved demand outlook India Equity Research Cement UltraTech Cement s (UTCL) Q1FY15 EBIDTA of INR10.5bn (~5% below estimates) was down ~2% YoY despite robust volume growth
More informationKirloskar Brothers Ltd.: Q1FY18 Result Update
Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Edelweiss Investment Research Kirloskar Brothers Ltd.: Q1FY18 Result Update
More informationINTERGLOBE AVIATION Yield pressure moderates
RESULT UPDATE INTERGLOBE AVIATION Yield pressure moderates India Equity Research Aviation InterGlobe Aviation s (IndiGo) Q4FY17 revenue grew a decent 19% YoY to INR48.5bn driven by 26% YoY spurt in RPKM.
More informationKEI INDUSTRIES Firing on all cylinders; growth visibility improving
RESULT UPDATE KEI INDUSTRIES Firing on all cylinders; growth visibility improving India Equity Research Consumer Durables KEI Industries (KEI) posted strong turnkey revenue, leading to 17% revenue beat
More informationLUPIN Improving outlook
RESULT UPDATE LUPIN Improving outlook India Equity Research Pharmaceuticals Lupin s Q2FY13 PBT at INR4.4bn (27%YoY) was ahead of the estimated INR3.9bn while PAT at INR2.9bn was in-line (higher tax rate
More informationBUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights
JK 20 NOV 2017 Quarterly Update BUY Target Price: Rs 1,220 White cement steals the show JK Cement s (JKCE) Q2FY18 EBITDA at Rs 2.1 bn (up 30% YoY) was higher than our and consensus estimates, mainly due
More informationMAHINDRA & MAHINDRA Eventful FY19 Success of UVs critical
VISIT NOTE MAHINDRA & MAHINDRA Eventful FY19 Success of UVs critical India Equity Research Automobiles Our recent meeting with Mahindra & Mahindra s (M&M) management indicated their positive outlook on
More informationGUJARAT PIPAVAV PORT Cost rationalisation continues to bear fruits
India Midcaps RESULT UPDATE GUJARAT PIPAVAV PORT Cost rationalisation continues to bear fruits India Equity Research Infrastructure - Ports Key highlight of Gujarat Pipavav Port s (GPPV) Q4FY17 result
More informationMarico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015
RESULTS REVIEW 4QFY15 29 APR 2015 Marico Kaya INDUSTRY FMCG CMP (as on 28 Apr 2015) Rs 1,635 Target Price Rs 1,823 Nifty 8,240 Sensex 27,226 KEY STOCK DATA Bloomberg MAKA IN No. of Shares (mn) 13 MCap
More informationMCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176
: price: EPS: Tepid volume growth continues 4QFY15 traded volumes in MCX showed a small improvement sequentially whereas declined yoy. FY15 traded Values are at a sever year low. We retain our cautious
More informationSUN TV NETWORK IPL bonanza further leg up to ARASU digitisation
COMPANY UPDATE SUN TV NETWORK IPL bonanza further leg up to ARASU digitisation India Equity Research Media Star India has bagged the Indian Premier League s (IPL) digital and television media rights for
More informationBAJAJ ELECTRICALS Change underway
COMPANY UPDATE BAJAJ ELECTRICALS Change underway India Equity Research Consumer Durables We hosted Bajaj Electricals (BJE) management at our recent investors meet. Key takeaways Range and Reach Expansion
More informationNear-term pressure, but long-term outlook positive
INDUSTRY IT CMP (as on 2 Nov 2015) Rs 1,812 Target Price Rs 2,050 Nifty 8,051 Sensex 26,559 KEY STOCK DATA Bloomberg ECLX IN No. of Shares (mn) 30 MCap (Rs bn) / ($ mn) 55/843 6m avg traded value (Rs mn)
More informationGATEWAY DISTRIPARKS. Higher throughput offsets lower realisation. Mumbai CFS reports throughput of 65,384 TEUs, up 28.4% QoQ
India Midcaps RESULT UPDATE GATEWAY DISTRIPARKS Higher throughput offsets lower realisation India Equity Research Logistics Gateway Distriparks (GDL) Q1FY13 standalone revenues were higher than our expectations
More informationHCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760
: price: EPS: How does our one year outlook change? HCLT registered a strong quarter with revenues growing at 6.5% qoq (4% qoq organic) including $40m contribution from Volvo, after a disappointing show
More informationKey estimate revision. Financial summary. Year FY16E 29, % 3,583 2, FY17E 26, % 3,478 2,
: price: EPS: How does our one year outlook change? We maintain our negative stance on SKF India due to the absence of significant growth momentum drivers over the medium term. While railways could be
More informationSQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E
Company Update Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E EBITDA Margins recovered by 618 bps QoQ: The company has witnessed many challenges over the year FY17 starting
More informationHOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance
RAMCO S HOLD Target Price: Rs 503 Deleveraging story playing out Ramco Cements total debt reduced by a massive Rs 5 bn to Rs 22 bn in FY16. The company generated total EBITDA of Rs 11.5 bn in FY16 and
More informationJSW STEEL Flexing realisation spreads
COMPANY UPDATE JSW STEEL Flexing realisation spreads India Equity Research Metals and Mining JSW Steel s realisation spread has gone up to INR5,900/t for 9mFY12 vs INR4,400/t in FY11. We revise up our
More informationADANI PORTS AND SEZ Another feather in the cap
EVENT UPDATE ADANI PORTS AND SEZ Another feather in the cap India Equity Research Infrastructure - Ports Adani Ports and SEZ (Adani Ports) will be setting up its fourth container terminal in 50:50 joint
More informationDLF Q4 miss; sluggish operations persist
RESULT UPDATE DLF Q4 miss; sluggish operations persist India Equity Research Real Estate DLF s residential new sales continued to remain lackluster in Q4FY17. We expect this to continue in ensuing quarters
More informationKey estimate revision. Financial summary. Year
: price: EPS: How does our one year outlook change? We retain our positive outlook on WIL and believe that revival in MHCV industry, increasing content per vehicle and opportunity in exports would drive
More informationTHYROCARE TECHNOLOGIES Performance dented by increased competition
RESULT UPDATE THYROCARE TECHNOLOGIES Performance dented by increased competition India Equity Research Healthcare Thyrocare Technologies (Thyrocare) Q2FY18 earnings came in weaker than expected as revenue
More informationHOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights
AMBUJA S 4 MAY 2017 Quarterly Update HOLD Target Price: Rs 232 Margins to improve from Q2 Q1CY17standalone EBITDA at Rs 4.0 bn was in line withconsensus estimate.volume was up 3% YoY to 6 mnt. Realization
More informationCummins India Ltd Bloomberg Code: KKC IN
Company Update Margins Under Pressure; Domestic Recovery Underway Half-yearly revenue was flat; margins were under pressure: Cummins India revenue, EBITDA and PAT for H1FY17 reached to Rs.24,784mn, Rs.4,649mn
More informationBHARAT ELECTRONICS Cruising in high growth orbit
RESULT UPDATE BHARAT ELECTRONICS Cruising in high growth orbit India Equity Research Defence Bharat Electronics (BEL) has sprung a strong execution surprise for 2 consecutive quarters led by pick-up in
More informationColgate-Palmolive (India)
Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue
More informationCADILA HEALTHCARE Positives on Horizon
VISIT NOTE CADILA HEALTHCARE Positives on Horizon India Equity Research Pharmaceuticals Post our interaction with Mr. Pankaj Patel, CMD, Cadila Healthcare, we highlight our takeaways on business. We upgrade
More informationGULF OIL LUBRICANTS GST booster; market share gains on course
VISIT NOTE GULF OIL LUBRICANTS GST booster; market share gains on course India Equity Research Lubricants We met the management of Gulf Oil Limited (GOLI) to understand the company s evolving strategy
More informationKalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256
: price: EPS: How does our one year outlook change? We expect KPP s revenue (standalone) to grow by 21% y-o-y in FY17E backed by an order book of Rs. 91bn (1.7x FY17E book-to-bill). Both Transmission line
More informationHe is BTech from IIT Bombay ( , Aeronautical Engineering) and MS from Cornell University ( , Mechanical Engineering).
Stabilizing the Ship; focus shifts to strategy Infosys has appointed Mr. Salil S Parekh as CEO and MD effective January 2, 2018 for a period of 5 years. He would be based out of Bengaluru (India). Also,
More informationVisaka Industries Ltd
Company Update Superior Product Mix & New Age Markets to Aid Growth New investments to aid growth: Visaka continues to give a good set of numbers. YoY EPS grew at 142% aided by a revenue growth of 1.5%
More informationHINDUSTAN ZINC New frontiers to keep up the zing
RESULT UPDATE HINDUSTAN ZINC New frontiers to keep up the zing India Equity Research Metals and Mining We reiterate BUY on Hindustan Zinc (HZL) with TP of INR395, implying 20% upside from current levels
More informationBHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188
RESULTS REVIEW 1QFY15 13 AUG 2014 BHEL SELL INDUSTRY CAPITAL GOODS CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188 Nifty 7,727 Sensex 25,881 KEY STOCK DATA Bloomberg/Reuters BHEL IN/BHEL.BO No. of Shares
More informationRamco Cement. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.415. Rs. 360
: price: EPS: How does our one year outlook change? We maintain our positive stance on s (TRCL). The company is one of the largest cement producers in South and remains among the best plays on Southern
More informationBUY. At inflection point NTPC. Target Price: Rs 197. Key highlights. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E.
At inflection point Q2FY18 adjusted PAT grew 12% YoY at Rs 27 bn (vs. our estimate Rs 26 bn) in tandem with 17% YoY rise in regulated equity. Core RoE is still healthy at 20.2% though it contracted ~174
More informationCONCRETE CALLING Headwinds on horizon; North first casualty
` CEMENT CONCRETE CALLING Headwinds on horizon; North first casualty India Equity Research Cement We perceive 2 recent developments as potential headwinds for the cement industry in the North: 1) the Supreme
More informationJamna Auto Industries
2QFY19 Result Update Institutional Equities Jamna Auto Industries Reuters: JMNA.NS; Bloomberg: JMNA IN Performance Below Expectations; Retain Buy Due To Strong Outlook Jamna Auto s 2QFY19 earnings were
More informationInfrastructure FY17 review
Infrastructure FY1 review Railways and roads continue stellar run Parvez Akhtar Qazi +91-22-403 5405 parvez.qazi@edelweissfin.com Rita Tahilramani +91-22-4040 440 rita.tahilramani@edelweissfin.com April
More informationCMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399
Company Update January 22, 2019 Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399 Multiple Growth Drivers in Place despite Near-term Headwinds Industries (SUNP) has released an investor
More informationKey estimate revision. Year CY14 87,383 11,148 6, CY15E 1,20,126 17,838 9,
: price: EPS: How does our one year outlook change? We retain our positive view on EIM on the back of expected improvement in volume and margin at Royal Enfield (RE) and expected revival in VECV on the
More informationAdani Ports & SEZ Rating: Target price: EPS:
Adani Ports & SEZ : price: EPS: Volume traction continues in a seasonally good quarter; maintain Adani Ports & SEZ reported a good quarter with total operating revenues (standalone) of Rs. 8.02bn and PAT
More informationBUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E
RAMCO S BUY Target Price: Rs 435 Efforts on cost cutting paying off Q2 EBITDA at Rs 2.8 bn (up 30% YoY) was ahead of our estimates due to lower-than-expected costs. Average costs (excluding freight) declined
More informationReliance Industries. Timing is everything BUY COMPANY UPDATE 1 OCT 2014
INDUSTRY OIL & GAS Timing is everything COMPANY UPDATE 1 OCT 2014 Reliance Industries BUY CMP (as on 30 Sep 2014) Rs 945 Target Price Rs 1,100 Nifty 7,965 Sensex 26,631 KEY STOCK DATA Bloomberg/Reuters
More informationGODREJ PROPERTIES Strong fundamentals priced in
RESULT UPDATE GODREJ PROPERTIES Strong fundamentals priced in India Equity Research Real Estate We see robust operations for Godrej Properties (GPL) going ahead given its new project pipeline, ability
More informationTTK Prestige. Channel-check takeaways Growth recovery pace sees moderation, competitive headwinds continue to prevail. Target CMP. Rating Rs.
Channel-check takeaways Growth recovery pace sees moderation, competitive headwinds continue to prevail Growth traction turns subdued in 4Q - Our channel-check interactions on a pan India basis is indicating
More informationTVS Motors. Source: Company Data; PL Research
Margins trajectory looking up ; Accumulate November 01, 2017 Saksham Kaushal sakshamkaushal@plindia.com +91 22 66322235 Poorvi Banka poorvibanka@plindia.com +91 22 66322426 Rating Accumulate Price Rs709
More informationFineotex Chemical Ltd
Company Update Decent Performance under Macroeconomic Pressure; Business Traction to Continue: Fineotex Chemical recorded decent set of result as consolidated sales grew by 1.1% YoY (largely in line) to
More informationResult Update. Sterling Tools. Buy
Sterling Tools Buy Result Update Growth momentum continues Sterling tools (STRT) number were broadly in line with estimates. Margins on a sequential basis have started showing signs of improvement at gross
More informationGillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance
2QFY19 Result Update Gillette India 13 February 2019 Reuters: GILE.NS; Bloomberg: GILL IN Marketing Investments Mask Improved Top-line Performance Gillette India s (GILL) 2QFY19 operating and net earnings
More informationCOLGATE PALMOLIVE Volumes recover; market share gains monitorable
RESULT UPDATE COLGATE PALMOLIVE Volumes recover; market share gains monitorable India Equity Research Consumer Goods Colgate Palmolive s (Colgate) Q4FY18 revenue growth of 5.2% YoY came in-line, whereas
More informationHINDUSTAN CONSTRUCTION CO. Arbitration money flow continues
India Midcaps RESULT UPDATE HINDUSTAN CONSTRUCTION CO. Arbitration money flow continues India Equity Research Infrastructure - Construction Hindustan Construction Company s (HCC) Q2FY18 profit came in
More informationKey estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,
: price: EPS: How does our one year outlook change? We retain our negative stance on the stock. We expect s revenue to de-grow by 9% y-o-y on the back of muted execution (client side and clearance delays)
More informationCESC Demerger prudent; prospects brighten
India Midcaps RESULT UPDATE CESC Demerger prudent; prospects brighten India Equity Research Power CESC has demerged operations into 4 different business segments, namely generation, distribution, retail
More informationBayer Cropscience (BYRCS IN)
(BYRCS IN) Rating: ACCUMULATE CMP: Rs4,258 TP: Rs4,517 February 4, 2019 Q3FY19 Result Update Change in Estimates Target Reco Change in Estimates Current Previous FY20E FY21E FY20E FY21E Rating ACCUMULATE
More informationMAHANAGAR GAS Volumes subdued; margin shines
RESULT UPDATE MAHANAGAR GAS Volumes subdued; margin shines India Equity Research Oil, Gas and Services Mahanagar Gas (MGL) Q1FY18 performance was a mixed bag. PAT, at INR1.2bn (up 34% YoY, 25% QoQ), surpassed
More informationBUY MULTI COMMODITY EXCHANGE OF INDIA. Strong Q2; All eyes on option volumes. Target Price: Rs 1,280. Concall highlights
25 OCT 2017 Quarterly Update BUY Target Price: Rs 1,280 Strong Q2; All eyes on option volumes Revenue increased ~5% QoQ to Rs 915 mn due to higher traded value (up ~17% QoQ) led by bullion (up ~17% QoQ)
More informationCentury Plyboards (India)
: price: EPS: How does our one year outlook change? We continue to maintain our positive stance on Century Plyboards (CPBI) as it is one of the leading players in the organized plywood market and third
More informationMRF. Result Update. Accumulate
Result Update MRF Accumulate Revenue disappoints MRF posted weak topline growth of 8.1% YoY at ` 38.6 bn for the quarter ended along with gross and EBITDA margins of 39.8% and 15.4% respectively. The gross
More informationCMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630
1QFY18 Result Update July 28,2017 CMP* (Rs) 208 Bloomberg Ticker CROMPTON IN Market Cap. (Rs bn) 130.6 Free Float (%) 65.6 Shares O/S (mn) 630 Channel De-stocking Impairs Top-line; Recovery Ahead Crompton
More informationHCL TECHNOLOGIES Weak revenue outlook shadows margin stability
RESULT UPDATE HCL TECHNOLOGIES Weak revenue outlook shadows margin stability India Equity Research IT HCL Technologies (HCLT) Q4FY18 revenue and operating margin at USD2,038mn (up 2.5% in USD) and 19.6%,
More informationMaruti Suzuki. Source: Company Data; PL Research
Healthy operating performance; Accumulate October 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating Accumulate Price Rs5,860 Target Price Rs6,356 Implied Upside 8.5% Sensex 27,916 Nifty
More informationCMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212
2QCY17 Result Update July 20, 2017 Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212 Well-placed in Power T&D Hi-tech Space; Order Book Remains Robust India s revenue rose by 6.0% YoY to Rs23.3bn
More informationSCHAEFFLER INDIA. Industrials rebound; robust domestic demand. Strong industrial rebound drives growth
RESULT UPDATE SCHAEFFLER INDIA Industrials rebound; robust domestic demand India Equity Research Bearing Schaeffler India s (Schaeffler) Q1CY18 sales grew 13% YoY (in line with estimate) led by strong
More informationPVR Weak content trips ATP and footfalls
RESULT UPDATE PVR Weak content trips ATP and footfalls India Equity Research Media PVR s Q2FY18 revenue and EBITDA came in line. Key positives were: i) 10% YoY jump in ad revenue despite weak content;
More informationInstitutional Equities
4QFY18 Result Update Institutional Equities Atul Auto 30 May 2018 Reuters: ATUL.BO; Bloomberg: ATUL IN Higher Expenses Mar Profitability Atul Auto s (AAL) 4QFY18 earnings missed our expectations on account
More informationDISH TV INDIA QoQ better quarter; merger benefits awaited
RESULT UPDATE DISH TV INDIA QoQ better quarter; merger benefits awaited India Equity Research Media Dish TV s Q1FY18 sales and EBITDA surpassed our expectations aided by 10.4% QoQ jump in ARPU. Key positives
More informationKey estimate revision. Year FY14 23,28,609 3,48,027 1,40, FY15E 25,74,029 3,94,133 1,69,
: price: EPS: How does our one year outlook change? We retain our positive stance on TTMT driven by continued strong performance at JLR on both revenues & margins and expected reduction in losses at standalone
More information